Ezetimibe for Patients With Chronic Hepatitis D

Inclusion Criteria: * Treatment experienced patients; non-responders of relapsers of pegylated interferon therapy * Age 18 years or above * Presence of anti-HDV in serum * Presence of quantifiable HDV RNA in serum * Elevated ALT \> ULN Exclusion Criteria: * Decompensated liver disease * Patients with ALT levels greater than 10 times ULN (400 U/L) * Pregnancy or inability to practice adequate contraception. * Significant systemic or major illnesses other than liver disease, including, but not limited to, congestive heart failure, renal failure (eGFR\<50 ml/min), organ transplantation, serious psychiatric disease or depression and active coronary artery disease. * Systemic immunosuppressive therapy * Evidence of another form of liver disease in addition to viral hepatitis * Active substance abuse, such as alcohol or injection drugs * Hepatocellular carcinoma * Concurrent hepatitis C infection or HIV coinfection * Diagnosis of malignancy in the five years * Concurrent usage of statins * Concurrent use of any other drug known to inhibit NTCP * Inability to understand or sign informed consent * Any other condition, which in the opinion of the investigators would impede the patient's participation or compliance in the study